Tumor Methylation Burden in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics
“One of the emerging biomarkers in lung cancer that is gaining attraction is Tumor Methylation Burden (TMeB) that represents a dynamic metric simultaneously reflecting the density and level of DNA methylation changes in multiple cancer-related genes or/and regions at a single “CpG” resolution. This is very useful for different reasons.
Firstly, TMeB assessment not only could be fundamental to discriminating lung tumor-derived from non-tumoral samples or monitoring clonal evolution during tumor recurrence.
Secondly, it could also help to identify and profile different histological and clinical lung cancer subgroups with high sensitivity and specificity.
In summary, the TMeB represents a burgeoning frontier in lung cancer management in the era of precision medicine.
Finally, the concept of epigenetics appears both exciting and overwhelming and could prove to be a game-changer.”
written by Federico Pio Fabrizio
Authors: Federico Pio Fabrizio and Lucia Anna Muscarella
Dr. Federico Pio Fabrizio is an Associate Professor of Molecular Biology at the Faculty of Medicine and Surgery at Kore University of Enna. He earned his degree in Medical, Veterinary, and Pharmaceutical Biotechnology from the University of Brescia and completed a PhD in Experimental and Regenerative Medicine at the University of Foggia, with a Postgraduate specialisation in Clinical Pathology and Clinical Biochemistry.
Before his current role, professor Fabrizio was a researcher in the Department of Oncology and Hemato-Oncology at the University of Milan. His research focuses on oxidative post-translational mechanisms in lung cancer and the role of epigenetic alterations as prognostic and predictive markers.
Further reading:
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NSCLC and Pancreatic Adenocarcinoma
FDA approves durvalumab for limited-stage small cell lung cancer
Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023